Compare Flux Power Holdings Inc (FLUX) vs 10X Genomics Inc (TXG) Price & Performance

FLUX trades at $0.461, down 5.96% today, amid a bearish technical signal and weak earnings. Revenue fell to $42M in 2026 with a net loss of $7M, though the P/S ratio of 0.22 suggests undervaluation. The company rejected an unsolicited acquisition proposal from Solidion Technology in October 2026, adding uncertainty. Analyst consensus remains unanimously bullish with 6 buy ratings, contrasting with negative profitability metrics like a -17.68% net income margin.

The outlook is mixed: strong analyst support and low valuation multiples offer potential upside if execution improves, but persistent losses, declining revenue, and acquisition resistance pose significant risks. Investors should weigh the bullish sentiment against fundamental weaknesses and recent volatility.

10x Genomics (TXG) trades at $77.28, up 1.55% on the day, with a bearish technical signal from moving averages. The company shows improving fundamentals with revenue of $642.82M in 2025 and a reduced net loss of -$43.54M, while recent news highlights strong demand for its Atera spatial biology platform and a patent victory. Positive earnings beats in recent quarters contrast with a high EV/EBITDA of 249.22, indicating significant growth expectations are priced in.

The outlook is mixed; analyst consensus is neutral with a $74.30 price target slightly below the current price, yet operational cash flow turned strongly positive in 2025. Key risks include persistent net losses, high valuation multiples, and execution on new product launches. The stock's near-term direction hinges on Atera's commercial success and achieving profitability.